Medical Oncology Clinical Trial
— THERANOVA-LIMOfficial title:
Impact of an Onco-haematology Vigilance Card in the Optimisation of the Town-hospital Relationship.
NCT number | NCT04931329 |
Other study ID # | 87RI21_0010 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | November 2, 2021 |
Est. completion date | June 2022 |
The objective of this study is to show the interest of setting up a drug vigilance card in Oncology in order to reinforce patient safety, develop compliance and avoid drug interactions when the patient consults town professionals or other specialists.
Status | Recruiting |
Enrollment | 100 |
Est. completion date | June 2022 |
Est. primary completion date | June 2022 |
Accepts healthy volunteers | |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - All patients treated at Limoges University Hospital in Medical Oncology department, receiving oral treatment (chemotherapy and/or targeted therapies) Exclusion Criteria: - All patients treated at Limoges University Hospital in Medical Oncology department, receiving hormone therapy or IV treatment only. |
Country | Name | City | State |
---|---|---|---|
France | CHU de Limoges | Limoges |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Limoges |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | measure patient satisfaction at 3 months | Patient satisfaction will be evaluated using IBM computer usability satisfaction questionnaires published by James R. Lewis (https://doi.org/10.1080/10447319509526110) | 3 months | |
Secondary | Measurement of caregiver satisfaction | Caregiver satisfaction will be evaluated using IBM computer usability satisfaction questionnaires published by James R. Lewis (https://doi.org/10.1080/10447319509526110) | 3 months | |
Secondary | Measurement of compliance reported by the GIRERD questionnaire | patients will have to answer shorts questions on GIRERD* questionnaire to evaluate their Medication compliance to oral anticancer drugs.
*X. Girerd, O. Hanon, K. Anagnostopoulos, C. Ciupek, J.J. Mourad, S. Consoli Assessment of antihypertensive compliance using a self-administered questionnaire: development and use in a hypertension clinic Presse Med, 30 (2001), pp. 1044-1048 |
3 months | |
Secondary | Measuring the satisfaction of treating physicians and health professionals | Treating physicians ad health professionnals satisfaction will be evaluated using IBM computer usability satisfaction questionnaires published by James R. Lewis (https://doi.org/10.1080/10447319509526110) | 3 months | |
Secondary | Evaluate the use of the QR code by health professionals/carers | The use of the QR code with be evaluated by counting how many times it will be flashed during study period. | 3 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02824042 -
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
|
Phase 1 | |
Completed |
NCT02253420 -
COPANLISIB (BAY80-6946) Drug-drug Interaction and Cardiovascular Safety Study in Advanced Solid Tumor and Non-Hodgkin's Lymphoma Patients
|
Phase 1 | |
Completed |
NCT02357953 -
Transpulmonary Thermodilution Using an Implented Central Venous Access Port
|
N/A | |
Completed |
NCT02645357 -
Implementing an Evidence-based Computerized Decision Support System Linked to Electronic Health Records to Improve Care for Cancer Patients
|
N/A | |
Terminated |
NCT02138812 -
Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
|
Phase 1 | |
Recruiting |
NCT05356182 -
A Pilot and Feasibility Study of a Dietary Intervention With Low-protein Meals in Cancer Patients Receiving Immunotherapies
|
N/A | |
Terminated |
NCT02368951 -
Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
|
Phase 1 | |
Not yet recruiting |
NCT05423808 -
Geriatric and Oncological Evaluation With Technology for Holistic Healthcare Management for Older Multimorbid Patients.
|
N/A | |
Terminated |
NCT02439346 -
Phase I Dose Escalation and Expansion of Oral BAY 1143269 in Combination With Intravenous Docetaxel
|
Phase 1 | |
Recruiting |
NCT05385718 -
Ezra Faster Scan Study
|
||
Completed |
NCT02457351 -
Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
|
Phase 1 | |
Completed |
NCT02906423 -
Results From a Health System-wide Implementation of a Quality of Life Questionnaire
|
N/A | |
Completed |
NCT01409135 -
A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
|
Phase 1 | |
Not yet recruiting |
NCT02327806 -
The Effect of Pullsed Magnetic Field Induction on Improving the Forearm Tissue Muscle Performance
|
N/A | |
Completed |
NCT02639091 -
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
|
Phase 1 | |
Completed |
NCT02366949 -
Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel
|
Phase 1 | |
Not yet recruiting |
NCT06097533 -
Improvement of Quality of Life by Cannabinoids in Oncologic Patients
|
Phase 2/Phase 3 | |
Completed |
NCT02427490 -
A Problem-Solving Intervention for Family Caregivers in Palliative Oncology
|
N/A | |
Recruiting |
NCT05359848 -
A Pilot, Feasibility Study of Intermittent Caloric Restriction Plus Plant-based Diet in Cancer Patients Receiving Chemotherapy
|
N/A |